Morgan Stanley Raises Gilead Target to $175

Morgan Stanley has lifted its price target for Gilead Sciences (GILD) from $171 to $175. The upgrade reflects analysts’ optimistic outlook on the company’s near‑term performance and product portfolio. The revision was driven by the potential of Gilead’s pipeline candidates in late‑stage clinical trials and the sustainability of its existing revenue streams. Analysts highlighted the firm’s therapeutic diversity and new partnerships as a solid foundation for long‑term growth. The new target implies an upside of X% relative to the current market price, signalling a potential improvement in the company’s valuation for investors. Morgan Stanley’s research note also emphasized that progress in drug development, regulatory approvals, and marketing strategies are expected to positively impact Gilead’s profitability. Investors are advised to assess this target within the context of their risk tolerance and prevailing market conditions. This is not investment advice.